CN103476753A - 新的瑞巴派特复合物和共晶体 - Google Patents
新的瑞巴派特复合物和共晶体 Download PDFInfo
- Publication number
- CN103476753A CN103476753A CN201280015913XA CN201280015913A CN103476753A CN 103476753 A CN103476753 A CN 103476753A CN 201280015913X A CN201280015913X A CN 201280015913XA CN 201280015913 A CN201280015913 A CN 201280015913A CN 103476753 A CN103476753 A CN 103476753A
- Authority
- CN
- China
- Prior art keywords
- rebamipide
- treatment
- eutectic
- effect
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (20)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161446573P | 2011-02-25 | 2011-02-25 | |
US61/446,573 | 2011-02-25 | ||
PCT/IB2012/050871 WO2012114317A1 (en) | 2011-02-25 | 2012-02-24 | Novel rebamipide complexes and cocrystals |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103476753A true CN103476753A (zh) | 2013-12-25 |
CN103476753B CN103476753B (zh) | 2015-12-09 |
Family
ID=45922723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280015913.XA Expired - Fee Related CN103476753B (zh) | 2011-02-25 | 2012-02-24 | 新的瑞巴派特复合物和共晶体 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9248196B2 (zh) |
CN (1) | CN103476753B (zh) |
HK (1) | HK1192888A1 (zh) |
WO (1) | WO2012114317A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103275000B (zh) * | 2013-06-19 | 2015-07-01 | 北京理工大学 | 瑞巴派特共晶的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040104020A (ko) * | 2003-06-02 | 2004-12-10 | 진양제약주식회사 | 신규 레바미피드 리지네이트와 레바미피드 아르기니네이트및 이 신규 레바미피드 리지네이트와 레바미피드아르기니네이트를 유효성분으로 함유하는 약학적 제제 |
CN1934086A (zh) * | 2004-01-21 | 2007-03-21 | 大塚制药株式会社 | 喹诺酮衍生物胺盐 |
CN101463005A (zh) * | 2009-01-08 | 2009-06-24 | 苏州中科天马肽工程中心有限公司 | 瑞巴派特粗品的提纯方法 |
JP2010043053A (ja) * | 2008-08-11 | 2010-02-25 | Dongwoo Syntech Co Ltd | 高純度のレバミピドの製造方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI80022C (fi) * | 1982-07-05 | 1990-04-10 | Otsuka Pharma Co Ltd | Foerfarande foer framstaellning av ett nytt, terapeutiskt anvaendbart karbostyrilderivat. |
CN1073418C (zh) | 1993-10-21 | 2001-10-24 | 大塚制药株式会社 | 白细胞介素-8生成抑制剂 |
JPH0971532A (ja) | 1995-09-06 | 1997-03-18 | Otsuka Pharmaceut Co Ltd | 発癌抑制剤 |
AR004214A1 (es) | 1995-10-12 | 1998-11-04 | Otsuka Pharma Co Ltd | Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas |
JP3093661B2 (ja) | 1995-10-12 | 2000-10-03 | 大塚製薬株式会社 | 眼疾患治療剤 |
ATE373502T1 (de) | 2003-07-30 | 2007-10-15 | Otsuka Pharma Co Ltd | Carbostyril-derivative zur beschleunigten speichelabsonderung |
-
2012
- 2012-02-24 WO PCT/IB2012/050871 patent/WO2012114317A1/en active Application Filing
- 2012-02-24 US US14/001,007 patent/US9248196B2/en not_active Expired - Fee Related
- 2012-02-24 CN CN201280015913.XA patent/CN103476753B/zh not_active Expired - Fee Related
-
2014
- 2014-06-25 HK HK14106408.7A patent/HK1192888A1/zh not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040104020A (ko) * | 2003-06-02 | 2004-12-10 | 진양제약주식회사 | 신규 레바미피드 리지네이트와 레바미피드 아르기니네이트및 이 신규 레바미피드 리지네이트와 레바미피드아르기니네이트를 유효성분으로 함유하는 약학적 제제 |
CN1934086A (zh) * | 2004-01-21 | 2007-03-21 | 大塚制药株式会社 | 喹诺酮衍生物胺盐 |
JP2010043053A (ja) * | 2008-08-11 | 2010-02-25 | Dongwoo Syntech Co Ltd | 高純度のレバミピドの製造方法 |
CN101463005A (zh) * | 2009-01-08 | 2009-06-24 | 苏州中科天马肽工程中心有限公司 | 瑞巴派特粗品的提纯方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103476753B (zh) | 2015-12-09 |
HK1192888A1 (zh) | 2014-09-05 |
US20140039005A1 (en) | 2014-02-06 |
US9248196B2 (en) | 2016-02-02 |
WO2012114317A1 (en) | 2012-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11760726B2 (en) | Crystalline solid forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl} -n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use | |
JP2017505796A5 (zh) | ||
JP2020158510A (ja) | 2−(tert−ブチルアミノ)−4−((1R,3R,4R)−3−ヒドロキシ−4−メチルシクロヘキシルアミノ)−ピリミジン−5−カルボキサミドの製剤 | |
CN110621662B (zh) | 一种盐的结晶性固体形式、制备工艺和使用方法 | |
JP2022003053A (ja) | Jak阻害剤を含む医薬組成物 | |
CA2879792A1 (en) | Multicomponent crystalline system comprising deferasirox and isonicotinamide and a process for the preparation thereof | |
TWI540131B (zh) | 阿瑞吡坦(aprepitant)l-脯胺酸組成物及共晶體 | |
CN112236413A (zh) | 结晶曲尼司特盐及其药物用途 | |
CN103476753B (zh) | 新的瑞巴派特复合物和共晶体 | |
US6482417B2 (en) | Stable pharmaceutical formulation comprising torsemide modification II | |
CN104159584A (zh) | 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体 | |
JP7453475B2 (ja) | オラパリブシュウ酸共結晶及びその医薬的使用 | |
US8871793B2 (en) | Metaxalone cocrystals | |
AU2022384750A1 (en) | Therapeutic cocrystals of 3-{[5-(azetidine-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1 s)-1 -methyl-2- (methyloxy)ethyl]oxy)-n-(5-methylpyrazin-2-yl)benzamide | |
NZ723714B2 (en) | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use | |
WO2020092376A1 (en) | Treating non-alcoholic steatohepatitis (nash) | |
ZA200306679B (en) | A stable pharmaceutical formulation comprising torsemide modification II. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1192888 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1192888 Country of ref document: HK |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: cambridge Patentee after: NUFORMIX Ltd. Address before: cambridge Patentee before: NUFORMIX Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151209 |